Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 18/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 12/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3869262 | 0.90 | ADORA2A (1.00) | ADORA2AADORA1TSHR | |
| SCHEMBL3873992 | 0.85 | ADORA2A (1.00) | ADORA2AADORA1TSHR | |
| SCHEMBL8245876 | 0.85 | ADORA2A (1.00) | ADORA2AADORA1TSHRPOLB | |
| SCHEMBL3878528 | 0.83 | ADORA2A (1.00) | ADORA2AADORA1TSHR | |
| SCHEMBL3869368 | 0.81 | ADORA2A (0.79) | ADORA2AADORA1TSHRPOLB | |
| SCHEMBL3869313 | 0.77 | ADORA2A (1.00) | ADORA2AADORA1 | |
| SCHEMBL16440392 | 0.77 | ADORA2A (0.73) | ADORA2AADORA1TSHRPOLB | |
| SCHEMBL8247472 | 0.77 | ADORA2A (0.62) | ADORA2AADORA1TSHRTP53POLB | |
| SCHEMBL3869046 | 0.75 | ADORA2A (1.00) | ADORA2AADORA1 | |
| SCHEMBL1256076 | 0.74 | ADORA2A (0.69) | ADORA2AADORA1TSHRPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090005568-A1 | Substituted 2-aminothiazoles for treating neurodegenerative diseases | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2009-01-01 | — | — | US | disclosed |
| US-20090005568-A1 | Substituted 2-aminothiazoles for treating neurodegenerative diseases | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2009-01-01 | — | — | US | disclosed |
| US-20090005568-A1 | Substituted 2-aminothiazoles for treating neurodegenerative diseases | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2009-01-01 | — | — | US | disclosed |
| WO-2007022415-A2 | SUBSTITUTED 2-AMINOTHIAZOLES FOR TREATING NEURODEGENERATIVE DISEASES | PHARMACOPEIA, INC. (US) | 2007-02-22 | — | — | WO | disclosed |
| WO-2007022415-A2 | SUBSTITUTED 2-AMINOTHIAZOLES FOR TREATING NEURODEGENERATIVE DISEASES | PHARMACOPEIA, INC. (US) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005568-A1 | Substituted 2-aminothiazoles for treating neurodegenerative diseases | ADORA2A, ADORA1, PARK7 | ADORA2A 1/4885ADORA1 2/4885TSHR 597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.